Chiesi Group Selects Salesforce Agentforce Life Sciences to Transform Customer Engagement
Summary (EN)
Salesforce announced on April 20 that Chiesi Group has selected Agentforce Life Sciences for Customer Engagement as part of a broader modernization of its global commercial operations. Chiesi, a biopharmaceutical company with more than 30 affiliates and sales in over 100 countries, said it wants a unified commercial ecosystem that can support healthcare-professional engagement, improve internal coordination, and preserve compliance in a tightly regulated environment. According to the release, the deployment will use Salesforce Data 360 to create a single trusted view of healthcare professionals, hospitals, and pharmacies, while Agentforce will support field representatives with AI-assisted preparation, summaries, note drafting, and cycle-planning tasks. Salesforce also said the platform will support event coordination, multichannel campaigns, and broader commercial lifecycle management. Chiesi framed the move not as a standalone AI experiment but as a company-wide transformation spanning commercial operations, scientific R&D, and manufacturing readiness in response to geopolitical, regulatory, and supply chain pressures. The announcement is notable because it ties agentic AI to a concrete, highly regulated enterprise workflow rather than a generic productivity narrative. It also provides evidence that major life sciences companies are beginning to move from legacy CRM systems toward AI-native commercial platforms while emphasizing privacy, responsible AI, and pharmaceutical compliance. The publication and the decision were both announced on April 20, keeping the item squarely within the required time window and making it a useful source for later analysis of enterprise AI adoption in real operating environments.
Summary (ZH)
Salesforce 于 4 月 20 日宣布，国际生物制药集团 Chiesi Group 已选择 Agentforce Life Sciences for Customer Engagement，以推动其全球商业运营体系升级。Chiesi 在全球拥有 30 多个分支机构，产品覆盖 100 多个国家。根据公告，该公司希望建立一个统一的商业生态系统，更高效地服务医疗专业人士，同时提升内部协同，并在高度监管的行业环境中保持合规。Salesforce 表示，此次部署将借助 Data 360 建立针对医疗专业人士、医院和药房的统一可信客户视图；同时，Agentforce 会为一线代表提供拜访准备、摘要生成、笔记起草和周期计划等 AI 辅助能力，减少重复性工作。平台还将支持活动协调、多渠道营销以及更广泛的商业全生命周期管理。Chiesi 将这一动作定义为组织级转型，而不是孤立的 AI 试点。公告指出，公司是在全球监管、地缘政治和供应链压力加剧的背景下，推动商业运营、科研研发和制造准备能力整体现代化。该消息的重要性在于，它把代理式 AI 直接绑定到医药行业真实且高度受监管的客户互动流程，而不是停留在泛化效率叙事层面。同时，这也显示出大型生命科学企业正开始从传统 CRM 体系转向 AI 原生商业平台，并明确把隐私保护、负责任 AI 和药事合规纳入上线条件。由于该决定与公告都发生在 4 月 20 日，因此完全符合本次任务的时效和事件约束。